Motor Neuron Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Motor Neuron Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major motor neuron disease markets reached a value of US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034.

The motor neuron disease market has been comprehensively analyzed in IMARC's new report titled "Motor Neuron Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Motor neuron disease refers to a group of progressive neurological disorders that affect the nerve cells responsible for controlling voluntary muscle movement. Some of the common symptoms include muscle weakness, often beginning in the hands, feet, or limbs; muscle stiffness and cramps; difficulty with coordination and balance; slurred or impaired speech; problems in swallowing; muscle twitching; muscle atrophy, etc. As the condition progresses, patients may experience increased difficulty with mobility, such as walking and fine motor tasks, as well as respiratory disorders. The diagnosis of motor neuron disease involves a comprehensive evaluation by healthcare professionals, typically including a neurologist. It begins with a detailed medical history and physical examination to assess symptoms, progression, and any family history of the ailment. Several diagnostic procedures, such as electromyography (EMG) and nerve conduction studies, can help determine the integrity of motor neurons as well as rule out further potential causes of muscle weakness. Numerous additional investigations, including blood tests, neuroimaging (MRI), lumbar puncture, etc., may be conducted to exclude other conditions and gather supportive evidence for confirming the diagnosis.

The increasing prevalence of inherited genetic mutations that can disrupt normal cellular processes, thereby leading to motor neuron degeneration, is primarily driving the motor neuron disease market. In addition to this, the growing cases of oxidative stress, caused by an imbalance between the production of reactive oxygen species and the body's ability to neutralize them, that lead to cellular damage are also creating a positive outlook for the market. Moreover, the widespread adoption of riluzole, which works by reducing glutamate levels in the brain, for slowing down disease progression and prolonging survival in patients is further bolstering the market growth. Additionally, various key players are making significant investments in R&D activities for introducing disease-modifying therapies that can reduce neuroinflammation, promote neuronal survival, enhance mitochondrial function, and target genetic mutations associated with the ailment. This, in turn, is also augmenting the market growth. Furthermore, the inflating demand for neuroprotective agents, such as antioxidants, mitochondrial regulators, glutamate modulators, etc., since they address oxidative stress, mitochondrial dysfunction, and glutamate excitotoxicity, is expected to drive the motor neuron disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the motor neuron disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for motor neuron disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the motor neuron disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the motor neuron disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the motor neuron disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current motor neuron disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the motor neuron disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the motor neuron disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the motor neuron disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of motor neuron disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of motor neuron disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of motor neuron disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with motor neuron disease across the seven major markets?
What is the size of the motor neuron disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of motor neuron disease?
What will be the growth rate of patients across the seven major markets?

Motor Neuron Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for motor neuron disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the motor neuron disease market?
What are the key regulatory events related to the motor neuron disease market?
What is the structure of clinical trial landscape by status related to the motor neuron disease market?
What is the structure of clinical trial landscape by phase related to the motor neuron disease market?
What is the structure of clinical trial landscape by route of administration related to the motor neuron disease market?